Bayer
VC Fund
Leverkusen, Germany
Bayer is an enterprise with core competencies in the life science fields of healthcare and nutrition. They design their products and services to help people and the planet thrive by supporting efforts to address unprecedented challenges. Their businesses include pharmaceuticals, consumer health, and crop science. They focus on developing andcommercializing products and solutions based on scientific knowledge.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries Bayer invests in
Stages Bayer invests in
Countries Bayer invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 12 (43%)
- Biotechnology 11 (39%)
- Medical 5 (18%)
- Agriculture 4 (14%)
- Life Science 4 (14%)
Stage
- Seed 7 (25%)
- Series A 5 (18%)
- Funding Round 5 (18%)
- Series B 3 (11%)
- Grant 2 (7%)
Country
- United States 16 (57%)
- United Kingdom 3 (11%)
- Canada 2 (7%)
- Spain 1 (4%)
- Brazil 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Juergen Eckhardt
Head at Bayer Venture Investments
|
Head at Bayer Venture Investments | Total investments: 40 | Find email | |
Jurg Eckhardt
SVP and Head of Leaps by Bayer
|
SVP and Head of Leaps by Bayer | Total investments: 3 | Find email | |
Paul Achleitner
Member of the Supervisory Board
|
Member of the Supervisory Board | Total investments: 0 | Find email | |
|
Andrew Chapple
Crop Science Division, representing SETAC DRAW
|
Crop Science Division, representing SETAC DRAW | Total investments: 0 | Find email | |
|
Antoine Bernet
President
|
President | Total investments: 1 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Soufflé Therapeutics
|
Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | Seed / Dec 31, 2023 | |
Food Banks Canada
|
Food Banks Canada is a national charitable organization dedicated to helping Canadians living with food insecurity. | Grant / Nov 28, 2023 | |
OME Health
|
OME Health is a client health support and practice management platform. The platform enables real-time monitoring of clients' progress using data from smart devices, a food diary, and app interactions. Additionally, it lessens administrative workload to allow the user to scale while keeping attention to the clients' needs and professionaladvancement. | Seed / Jun 20, 2022 | |
MagGrow
|
Agricultural Magnetics Limited is an Irish company that produces innovative patented technology called MagGrow into the agricultural industry.The MagGrow system is a patented, proprietary technology for droplet formation that yields superior spray drift-reduction and spray coverage performance.MagGrow customers are seeing two core benefits ofup to 70% drift reduction and typical coverage of at least 20-40%. The MagGrow technology delivers significant savings in pesticide usage, scarce resources such as water and labor, extends spray windows and meets environmental and legislative requirements. . The agricultural spray technology operates across three global footprints, the USA, Canada, and Europe. | Non-equity Assistance / Sep 09, 2021 | |
Grão Direto
|
The agriculture that has so much technology inside the gate and gives lessons of modernity to Brazil and to the world can also be so technological and modern in the commercialization of its products!The Grão Direto forms a web between buyers and producers of grains connected in a much more intelligent way.Through technology, they can interactdigitally and much faster and more efficiently. This is either for spot, future or barter trading. Grão Direto was created with the necessary flexibility to support all the chain's profiles: cooperatives, tradings, traditional brokers, feed factories, warehouses, traders and much more.The platform generates market intelligence gains for producers and buyers to make better decisions, as well as more agility in processes associated with marketing (logistics, contract management, financial products and more). | $3.3M / Mar 01, 2021 | |
Elly
|
Elly is the world's first empathetic audio companion for patients living with chronic disease. | Nov 17, 2020 | |
|
Elly
|
Elly is the world's first empathetic audio companion for patients living with chronic disease. | Seed / Nov 17, 2020 | |
OneDrop
|
One Drop is a diabetes management platform that helps people navigate diabetes together. It is an app for a diabetes management company. The app was created by Jeff Dachis, a co-founder of Razorfish, launched in the App Store this April as a way to help diabetics keep a running log of their personal insulin levels, the effectiveness of theirmedication, what they recently ate and what types of activities are affecting their blood sugar on a daily basis.It was incorporated in 2014 and is based in New York. | $34.7M / Series C / Aug 24, 2020 | |
Oerth Bio
|
Oerth Bio is a developer of targeted protein degraders for agricultural applications. The company leverages Arvinas' novel PROTAC protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and gynecological diseases. | $55M / Corporate Round / Feb 27, 2020 | |
Immunitas Therapeutics
|
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies. | $39M / Series A / Nov 21, 2019 | |
| See all 28 investments → | |||
Co-Investors
Leaps by Bayer
7 deals together
Ginkgo Bioworks
2 deals together
Global Millennial Capital
2 deals together
3i Group
1 deal together
Agent Capital
1 deal together
Alexandria
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bayer invest in?
Bayer invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bayer?
Public channels for Bayer include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bayer?
The team at Bayer includes Juergen Eckhardt (Head at Bayer Venture Investments), Jurg Eckhardt (SVP and Head of Leaps by Bayer) and Paul Achleitner (Member of the Supervisory Board), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
